ReviewPharmaceutics2024
Liposomes and Other Nanocarriers for the Treatment of Acne Vulgaris: Improved Therapeutic Efficacy and Skin Tolerability.
Review in Pharmaceutics, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 26 citations in OpenAlex.
- The Therapeutic Effects of a Bentonite-Based Facial Mask With Alcea sulphurea Extract on Acne Severity and Patient Experience: Add-On Randomized Controlled Clinical Trial.Journal of cosmetic dermatology · 2025Trial
- Liposomal Formulation of Bioactive Substances fromInternational journal of molecular sciences · 2026Article
- Chloramphenicol Application Onto the Eyelid: Transfersomes for Enhanced Skin Delivery.AAPS PharmSciTech · 2026Article
- Decoding Cyclodextrins in Skin Applications: Structure, Mechanisms, and Safety in Cosmetic and Dermatologic Formulations (Part I).International journal of molecular sciences · 2026Review
- Dual drug co-encapsulation into liposomes and liposome-derived nanosystems for improved synergistic treatment of skin diseases.Drug delivery and translational research · 2026Review
- Harnessing liposomal delivery to boost polyphenols' potential in chronic wound therapy.Frontiers in drug delivery · 2026Article
- Lipid-Based Nanocarriers as a Promising Delivery System in the Management of Acne.Current pharmaceutical design · 2026Review
- Dissolved bubble microneedle patches for co-delivery of hydrophobic and hydrophilic drugs to improve acne vulgaris therapy.Microsystems & nanoengineering · 2025Article
- An Updated Perspective on Skin Disease Therapy: From Conventional Methods to Nanocarrier Innovations.AAPS PharmSciTech · 2025Review
- Nanovesicles and Human Skin Interaction: A Comparative Ex-Vivo Study.Nanomaterials (Basel, Switzerland) · 2025Article
- Nanoparticle-Encapsulated Plant Polyphenols and Flavonoids as an Enhanced Delivery System for Anti-Acne Therapy.Pharmaceuticals (Basel, Switzerland) · 2025Review
- Emulgel-Based Formulations of Clobetasol Propionate: Formulation Development, Characterization, and Pharmacological Evaluation.Pharmaceutical nanotechnology · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Acne vulgaris is a common dermatologic disorder that affects approximately 85% of teenagers, which significantly impacts the quality of life in adolescents. It is a chronic disease of the sebaceous follicles that is multifactorial in etiology. Topical treatment is the first choice for mild and moderate acne, while systemic therapy is reserved for severe and certain moderate cases. Topical treatments include retinoids (e.g., tretinoin and adapalene), antibiotics (e.g., clindamycine), and other agents (e.g., benzoyl peroxide and azelaic acid), often applied in combination. The mechanisms of action include antimicrobial, anti-inflammatory, and keratolytic activities, as well as sebum secretion reduction, and the normalization of follicular keratinization. However, these topical agents commonly induce side effects, such as dryness, burning, stinging, peeling, redness, erythema, and photosensitivity. Therefore, there is a need to reduce the side effects of anti-acne drugs, while maintaining or enhancing their therapeutic effectiveness. This article aims to comprehensively outline nanotechnology strategies, particularly the use of phospholipid-based nanocarriers like liposomes and related vesicles, to enhance therapeutic efficacy, skin tolerability, and patient compliance in the treatment of acne vulgaris. In addition, novel active ingredients encapsulated in vesicles beyond those recommended in official guidelines are discussed.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.